Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Pharmaceuticals
    • Sanofi plans to create...

    Sanofi plans to create standalone company dedicated to making APIs

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-26T15:37:12+05:30  |  Updated On 26 Feb 2020 3:37 PM IST
    Sanofi plans to create standalone company dedicated to making APIs

    PARIS : Sanofi plans to create a standalone company dedicated to making active pharmaceutical ingredients (API), components that are biologically active in a drug, and will decide whether to list it on Euronext Paris by 2022.

    The French drugmaker on Monday said it would create the business on the back of the combination of its API commercial and development activities with six of its European API production sites in Italy, Germany, Britain, France and Hungary.

    Europe's pharmaceutical sector is highly dependent on raw materials and active ingredients from Asia, buying products from companies mostly based in China and India.

    Sanofi said the new group will be headquartered in France, operate with at least 3,100 skilled employees and have sales estimated at about 1 billion euros ($1.1 billion) by 2022.

    "Sanofi is fully committed to the new company's success and intends to establish a long-term customer relationship with the new API supplier and to hold a minority stake of approximately 30% in the new company," it said in a statement.

    Philippe Luscan, a Sanofi executive vice president in charge of global industrial affairs, said that carving out a new business would allow better access to clients and stronger growth.

    "Many pharmaceutical players see us as direct competitors. We believe having a standalone business would allow much better access and higher volumes in a market that, we believe, will grow by 6% per year," he told reporters, adding that staff representatives had responded favourably to the project.

    Read Also : Sanofi Joins Forces With US Department Of Health To Advance A Novel Coronavirus Vaccine

    Luscan said he believed that the business would rank as Europe's second-biggest API player by sales behind Switzerland's Lonza.

    France's CGT union said the announcement was detrimental to staff and was putting the future of factories at risk.

    "Clearly, the management is willing to outsource production. Retaining a 30% stake in the new entity is purely to look good," a spokesman for the union said.

    Monday's announcement follows a decision by Sanofi, which appointed a new chief executive last year, to carve out its consumer health business, home to over-the-counter products such as influenza treatment Tamiflu.

    That business will also operate as a standalone unit in addition to the group's three other main divisions.

    sanofiactive pharmaceutical ingredientsAPIpharma API
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok